Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

CD8+ T cell

  • CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
    You have access
    CD8-Targeted PET Imaging of Tumor-Infiltrating T Cells in Patients with Cancer: A Phase I First-in-Humans Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
    Michael D. Farwell, Raymond F. Gamache, Hasan Babazada, Matthew D. Hellmann, James J. Harding, Ron Korn, Alessandro Mascioni, William Le, Ian Wilson, Michael S. Gordon, Anna M. Wu, Gary A. Ulaner, Jedd D. Wolchok, Michael A. Postow and Neeta Pandit-Taskar
    Journal of Nuclear Medicine May 1, 2022, 63 (5) 720-726; DOI: https://doi.org/10.2967/jnumed.121.262485
  • You have access
    First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting
    Neeta Pandit-Taskar, Michael A. Postow, Matthew D. Hellmann, James J. Harding, Christopher A. Barker, Joseph A. O’Donoghue, Martha Ziolkowska, Shutian Ruan, Serge K. Lyashchenko, Frank Tsai, Michael Farwell, Tara C. Mitchell, Ron Korn, William Le, Jason S. Lewis, Wolfgang A. Weber, Deepak Behera, Ian Wilson, Michael Gordon, Anna M. Wu and Jedd D. Wolchok
    Journal of Nuclear Medicine April 1, 2020, 61 (4) 512-519; DOI: https://doi.org/10.2967/jnumed.119.229781
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire